CTIS2023-505287-11-01招募中1 期
Safety, tolerability, and biodistribution of [89Zr]Zr-DFO-APAC (Phase 0) in subjects with peripheral arterial occlusive disease / critical limb ischemia (PAOD/CLI) and healthy volunteers – an open label PET study (CHASE-study)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Aplagon Oy
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
A Phase I Study to Assess Biodistribution of 89Zr-CB307 in PSMA+ and PSMA-Tumour LesionsNL-OMON51775Cresendo Biologics Ltd12
进行中（未招募）
1 期
ptake of 89Zr-labeled ipilimumab measured with PET-scan in patients who are treated with ipilimumabMedDRA version: 21.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Advanced melanomaEUCTR2012-003616-31-NLVU medical center24
招募中
不适用
ptake and biodistribution of 89Zirconium-labeled ipilimumab in ipilimumab treated patients with metastatic melanomamelanoma10040900NL-OMON53144Vrije Universiteit Medisch Centrum22
尚未招募
不适用
Opname en biodistributie van 89Zirconium gelabeld ipilimumab in melanoompatiënten die behandeld worden met ipilimumabNL-OMON27886VU University Medical Center29
招募中
早期 1 期
Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)Peripheral Arterial Occlusive DiseaseCritical Limb IschemiaNCT06204237Aplagon Oy10